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Abstract
HIV-1/HAART-associated lipodystrophy syndrome (HALS) has been associated with exposure to stavudine (d4T) through
mitochondrial dysfunction. We performed a 48-week study to assess the effects of switching from d4T to raltegravir (RAL)
on metabolic and fat molecular parameters of patients with HALS. Forty-two patients with HALS and a median exposure to
d4T . 7 years were switched to RAL and followed for 48 weeks. Fasting metabolic tests, HIV RNA, CD4 cell count, and fat
measured by DEXA were obtained at baseline and week 48. mtDNA and gene transcripts for PPAR gamma, adiponectin,
cytochrome b, Cox IV, TNF alpha, MCP-1 and CD68 were assessed in paired subcutaneous fat tissue biopsies. Lipid
parameters, fasting glucose, insulin, and HOMA-IR did not change significantly. Whole body fat (P = 0.0027) and limb fat
mass (P,0.0001) increased from baseline. Trunk/limb fat ratio (P = 0.0022), fat mass ratio (P = 0.0020), fat mass index
(P = 0.0011) and percent leg fat normalized to BMI (P,0.0001) improved after 48 weeks. Relative abundance of mtDNA,
expression of PPAR gamma, adiponectin, Cyt b, and MCP-1 genes increased, whereas Cox IV, TNF alpha, and CD68 did not
change significantly from baseline. Switching from d4T to RAL in patients with HALS is associated with an increase in limb
fat mass and an improvement in markers of adipocyte differentiation and mitochondrial function in SAT.
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Introduction
The landscape of HIV-1 infection has been changed forever by
the availability, in developed countries, of highly active antiretro-
viral therapy (HAART) since 1996. However, the doubtless
efficacy of HAART is still shadowed by significant toxicity,
especially long-term toxicity [1]. Among antiretroviral drug-
associated toxicity, that associated with the use of nucleoside
reverse transcriptase inhibitors (NRTI) stands out [2]. HIV-1/
HAART-associated lipodystrophy syndrome (HALS) is one of the
most severe adverse effects related to NRTI use, especially with
stavudine (d4T) for which there is overwhelming epidemiological
evidence linking its use to the development of HALS [1,3].
Management strategies for HALS have included diet modifica-
tions, switches from NRTI to other drugs and pharmacological
interventions [1,3]. However, the results for most of these
strategies have been quite disappointing in terms of reversing
lipoatrophy [1,3]. Among partially successful strategies, switching
between NRTI, especially from thymidine analogues to abacavir
(ABC) or tenofovir (TDF) has been associated with significant limb
fat gains [4,5].
Raltegravir (RAL) is the first integrase inhibitor and it has
exhibited a benign safety profile with no known deleterious effects
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on fat content in clinical trials [6]. We measured fat content
changes over time in virologically controlled HIV-1-infected
patients switching from d4T to RAL. In addition, in a subgroup
of patients, changes in expression of molecular markers in
subcutaneous adipose tissue (SAT) level were also studied. Our
working hypothesis was that such a change would induce an
increase in subcutaneous fat and an improvement in molecular
parameters in SAT in these patients.
Patients and Methods
Subjects
All patients for this observational study were recruited through
three HIV-1 infection clinics, between July 2008 and December
2009, at the Hospital de la Santa Creu I Sant Pau in Barcelona, and
Hospital Clı́nico and Hospital de la Princesa, the latter two in Madrid.
They attend a population of 3800 HIV-1-infected patients on
active follow-up. Patients recruited for this study were those with
HIV infection, treated with a d4T-based antiretroviral regimen
who had clinically-evident HALS. Exclusion criteria included
previous use of RAL, including failure with a RAL-based regimen,
and the absence of HALS. At baseline, d4T was switched to RAL
whereas the other two drugs of the regimen remained unchanged
until week 48.
At the time of study entry no patient used any other drug known
to influence glucose metabolism or fat distribution such as anabolic
hormones or systemic corticosteroids, uridine, recombinant
human growth hormone, or appetite stimulants. The diagnosis
of AIDS was based on the 1993 revised case definition of the
Centers for Disease Control and Prevention [7]. Written informed
consent was obtained from the patients at study entry. The study
was approved by the Ethics Committees of the Hospital de la
Santa Creu i Sant Pau, Hospital Clı́nico de San Carlos and
Hospital de la Princesa.
Body composition measurements
Subjects were weighed on calibrated scales after removing
shoes, outdoor clothing, and other heavy items. Body mass index
(BMI) was calculated by dividing the weight in kilograms by the
square of the height in meters. Waist circumference was measured
to the nearest millimeter using anatomical landmarks as defined
for the Third National Health and Nutrition Evaluation Survey
[8].
Whole body dual energy X-ray absorptiometry (DEXA) scans
(Hologic QDR-4500A Hologic, Inc, 590 Lincoln St, Waltham,
MA 02154, USA) were conducted by a single operator at each site
on all the patients. Instruments were calibrated daily. The
percentage fat at the arms, legs and central abdomen (calculated
from the mass of fat versus lean and bone mass) as well as total
lean body mass in kilograms was recorded. All DEXA scans were
centrally read by the same evaluator (LDR, CETIR), blind to
patient therapy. We measured fat symmetry distribution, the
following fat ratios were analyzed, trunk/limb fat ratio by dividing
trunk fat by limb fat [1], fat mass ratio by dividing the percentage
of trunk fat by the percentage of lower limb fat [9], fat mass index
by dividing whole body fat by squared height in meters [10], and
leg fat percentage normalized to BMI by dividing the percentage
of leg fat mass by BMI [11].
Definition of HALS and metabolic syndrome
Lipoatrophy was identified by patient self-reporting and/or
clinician observation of relevant changes to the face (loss of cheek
and/or preauricular fat pads), arms, legs, and subcutaneous
abdominal tissue, and confirmed clinically by qualitative physical
examination. Lipohypertrophy was diagnosed by the presence of
central adiposity which was defined by a waist-hip ratio (WHR) of
.0.90 in men, and .0.80 in women) [8], breast enlargement in
women or the appearance of cervical fat pads or supraclavicular
fat accumulation [12]. Both clinical situations occurred in an
isolated manner or concomitantly and any combination of them
was considered to be a mixed syndrome.
Visual aspects of HALS were assessed with the Lipodystrophy
Severity Grading Scale (LSGS) based on that reported by
Lichtenstein et al. [12]. In addition, facial lipoatrophy was also
assessed through the scale of Fontdevila et al. [13] which
established four degrees of facial lipoatrophy ranging from normal
to grade three (or severe). A severe loss of SAT was defined as
baseline limb fat ,3 kg. The metabolic syndrome was defined
according to the U.S. National Cholesterol Education Program
(NCEP) Adult Treatment Panel III Guidelines [14] and modified
as recommended in the latest American Heart Association/
National Heart, Lung, and Blood Institute Scientific Statement
[15].
Biochemistry laboratory measurements
All laboratory investigations were performed after a 12 hour
overnight fast and at least 15 minutes after the placement of a
peripheral intravenous catheter. Patients were seated during blood
drawing and abstained from smoking at least 15 minutes before
sampling; tourniquet use was avoided when possible and, if not,
was maintained for less than 1 minute. All lipid measurements
were performed in a Hitachi 911 system from Roche (Basel,
Table 1. Demographics and viro-immunological status of the
population studied.
Parameter Value
Age in years, median (IQR) 45.6 (41.4–50.0)
Men, n (%) 32 (76.2)
Means of HIV-1 infection
MsM (%) 16 (38.1)
HTSX (%) 9 (21.4)
IDU (%) 17 (40.5)
Years since diagnosis, years, median (IQR) 14 (10–21)
Smokers, n (%) 25 (59.5)
Prior AIDS, n (%) 27 (64.3)
HCV co-infection, n (%) 26 (61.9)
HCV treatment completed, n (%) 5 (31.2)
HBV co-infection, n (%) 1 (2.4)
Baseline CD4, median (IQR), cells/mm3 603 (389–901)
CD4 increase (IQR), cells/mm3 412 (258–573)
Nadir CD4 cell count ,100 cells/mm3 (%) 14 (33.3)
Nadir CD4 cell count ,200 cells/mm3 (%) 29 (69.0)
Baseline viral load, median (IQR), log10, copies/ml 1.28 (1.28–1.28)
Maximum viral load $5 log10, copies/ml (%) 26 (61.9)
Viral load decrease, median (IQR), log10, copies/ml 4.1 (3.6–4.7)
All values expressed as median (IQR = interquartile range) unless
otherwise specified, MsM = men who have sex with men, HTSX =
heterosexuals, IDU = intravenous drug users, AIDS = acquired
immune deficiency syndrome, HCV = hepatitis C virus, HBV =
hepatitis B virus, CD4 increase = current CD4-CD4 prior to starting of
antiretroviral therapy, IQR = interquartile range.
doi:10.1371/journal.pone.0089088.t001
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Switzerland). Serum total cholesterol and triglycerides were
measured by fully enzymatic standard method and high-density
lipoprotein (HDL) cholesterol by a direct method using polyeth-
ylene glycol modified enzymes (PEGME) [16]. Low density
lipoprotein (LDL) cholesterol was measured after ultracentrifuga-
tion according to the Lipid Research Clinic recommended
method, but utilizing the PEGME method for HDL cholesterol
instead of precipitation. Insulin resistance was estimated by the
homeostasis model assessment method (HOMA-IR) as the product
of the fasting concentrations of plasma insulin (munits/ml) and
plasma glucose (mmol/l) divided by 22.5 [17].
Fat tissue samples, mitochondrial DNA and gene
expression studies in SAT
Fat tissue samples were retrieved at baseline and 48 weeks after
switching. They were obtained from SAT abdominal depot
through a small surgical biopsy performed by an 8 mm punch
under local anesthesia with mepivacaine. The SAT obtained was
immediately frozen in liquid nitrogen and stored at 280uC until
RNA extraction (see below). The amount of mitochondrial DNA
was determined as previously reported [18] and expressed as the
relative amounts of mtDNA per nuclear DNA. The expression of
gene transcripts encoding for proteins relevant to adipocyte
biology and function was assessed: peroxisome proliferator-
activated receptor gamma (PPAR gamma), and adiponectin to
explore adipocyte differentiation, Cyt b and cytochrome oxidase
subunit IV (Cox IV) to explore mitochondrial toxicity, and tumor
necrosis factor alpha (TNF alpha), monocyte chemotactic protein-
1 (MCP-1) and CD68 (a signal of macrophage infiltration) to
explore inflammation. After homogenization of tissue samples in
RNeasy lysis buffer (Qiagen, Hilden, Germany), RNA was isolated
using a column-affinity based methodology that included on-
column DNA digestion (RNeasy; Qiagen). One microgram of
RNA was transcribed into cDNA using MultiScribe reverse
transcriptase and random-hexamer primers (TaqMan Reverse
Transcription Reagents; Applied Biosystems, Foster City, Califor-
nia, CA, USA). For quantitative mRNA expression analysis,
TaqMan reverse transcriptase (RT)-polymerase chain reaction
(PCR) was performed on the ABI PRISM 7700HT sequence
detection system (Applied Biosystems). The TaqMan RT-PCR
reactions were performed in a final volume of 25 ml using TaqMan
Universal PCR Master Mix, No AmpErase UNG reagent and
specific TaqMan primer pair probes: PPAR gamma, Hs00234592;
adiponectin, Hs00605917; cytochrome b, Hs02596867; COXIV,
Hs00266371; TNF alpha, Hs00174128; MCP-1, Hs00234140;
CD68, Hs00154355; RPLO, Hs9999902. Controls with no RNA,
primers, or RT were included in each set of experiments. Each
sample was run in duplicate, and the mean value of the duplicate
was used to calculate the mRNA levels for the genes of interest.
Values were normalized to that of the reference control (RPLO)
using the comparative 2-DCT method, following the manufactur-
er’s instructions. Parallel calculations performed using the
reference gene HPRT (Hs99999909) yielded essentially the same
results.
Table 2. Antiretroviral drug exposure in the population studied.
Parameter Value
ART before switching
IP-based, n (%) 27 (64.3)
NNRTI-based, n (%) 11 (26.2)
3 NRTIs, n (%) 2 (4.8)
IP+ NNRTI, n (%) 1 (2.4)
NRTI backbone before switching
d4T+3TC, n (%) 10 (23.8)
d4T+TDF, n (%) 26 (61.9)
d4T+ddI, n (%) 3 (7.1)
d4T+ABC, n (%) 2 (4.8)
d4T alone, n (%) 1 (2.4)
No. of combination antiretroviral regimens, median (IQR) 5 (3–6)
HAART duration, m 127.5 (98.0–150.0)
Cumulated Individual drug exposure
AZT exposure, m 12.0 (0.0–27.0)
AZT exposure, g 219.0 (0.0–492.1)
d4T exposure, m 89.0 (60.0–108.0)
d4T exposure, g 216.6 (146.0–262.8)
d4T exposure, mg/kg 1.046 (0.984–1.111)
ddI exposure, m 0.0 (0.0–21.0)
ddI exposure, g 0.0 (0.0–255.5)
ddC exposure, m 0.0 (0.0–0.0)
All parameters expressed as median and (interquartile range) unless otherwise specified. ART = Antiretroviral therapy, HAART = Highly active
antiretroviral therapy, IP = protease inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase
inhibitor, AZT = zidovudine, d4T = stavudine, ddI = didanosine, ddC = zalcitabine.
doi:10.1371/journal.pone.0089088.t002
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Statistical analyses
Data are expressed as median with inter-quartile range (IQR) or
as frequencies and percentages or otherwise specified. Continuous
variables were assessed with the Wilcoxon signed-rank test and the
Mann-Whitney test for dependent and independent data, respec-
tively. Categorical data were compared by use of the Fisher’s exact
test. Differences between baseline and 48-week data were assessed
with paired t test. The level of significance was established at 0.05
and all reported P values are two-sided. All analyses were
performed with the SAS version 9.2 software (SAS Institute Inc.,
Cary, NC). A logistic regression analysis was used to examine the
association of baseline parameters with limb fat gain $800 grams
over 48 weeks; variables associated with a P,0.1 in the bivariate
analyses were included in the multivariate stepwise analysis.
Results
Population studied and viro-immunological status
Forty-two Caucasian patients were recruited. There were 32
men (76.2%) and 10 women (23.8%), with a mean age of
45.367.43 years (median: 45.6 years [IQR: 41.5–50.0]). Demo-
graphic, viro-immunological, metabolic and fat parameters of
these patients were not different with respect to recruitment
center. Prior AIDS-defining conditions were present in more than
60% of the patients. The demographics, virological and immuno-
logical parameters are shown in table 1. Most of the patients (38,
90.5%) had undetectable viral load at baseline, and among those
with detectable viral load, the median was 148 (IQR: 70–288)
copies/ml. At week 48, 30 (71.4%) patients had undetectable viral
load (OR = 2.53; 95%CI: 0.76–9.15, P = 0.1508), and the median
viral load for those who had it detectable was 36 (IQR: 25–67)
copies/ml. No patient discontinued the study. There were no
patients with virologic breakthrough throughout 48 weeks.
Antiretroviral drug exposure
Most of the patients were highly antiretroviral-experienced with
a median prior exposure to 5 (IQR: 3-6) different combination
antiretroviral regimens. The d4T-based regimen was a salvage
regimen for 62% of patients. Antiretroviral drug exposure is
summarized in table 2.
Table 3. Anthropometric, metabolic and fat parameters at baseline and 48 weeks after switching from stavudine to raltegravir.
Parameter Baseline 48 weeks P value
Weight, kg 71.0 (59.5-77.5) 68.5 (60.0-78.5) 0.2626
BMI 23.07 (21.08-25.69) 23.07 (20.69-25.71) 0.1372
Waist circumference, cm 86.0 (79.5-99.0) 89.0 (82.2-96.2) 0.0464
WHR 0.94 (0.90-0.99) 0.95 (0.89-1.00) 0.3323
Systolic BP, mm Hg 120 (110-129.5) 120 (110.7-125.2) 0.9810
Diastolic BP, mm Hg 74.0 (70.0-80.0) 77.0 (70.0-80.0) 0.1386
Whole body fat, g 13184 (8950-16691) 14941 (9430-18303) 0.0027
Whole body fat, % 18.6 (15.3-23.7) 21.7 (16.1-26.3) 0.0037
Trunk fat, g 8192 (5324-10.379) 8362 (5541-11057) 0.0977
Left leg fat, g 987 (794-1707) 1305 (861-1962) ,0.0001
Limb fat mass, g 3352 (2519-5827) 4247 (2848-6589) ,0.0001
Trunk/limb fat ratio 2.19 (1.68-2.99) 1.97 (1.49-2.88) 0.0022
Fat mass ratio 1.92 (1.42-2.56) 1.87 (1.29-2.48) 0.0020
Fat mass index, kg/m2 4.57 (3.08-5.64) 5.04 (3.19-6.47) 0.0011
% left leg fat/BMI 0.47 (0.36-0.65) 0.52 (0.40-0.80) ,0.0001
Lean mass, g 55895 (44837-61047) 54653 (45059-58274) 0.1438
Lean mass/height2, kg/m2 18.69 (16.17-20.42) 18.01 (16.12-19.96) 0.9827
BMC, g 2208 (1969-2525) 2216 (1963-2448) 0.6035
BMD, g/cm2 1.10 (1.04-1.19) 1.09 (1.03-1.18) 0.2036
Metabolic syndrome, n (%) 17 (40.5) 21 (50.0) 0.5111
Total cholesterol, mg/dl 191 (152-240) 196 (158-221) 0.8216
Triglycerides, mg/dl 171 (113-250) 203 (122-259) 0.2245
HDL cholesterol, mg/dl 44 (38-56) 41 (37-55) 0.9643
Total cholesterol/HDL ratio 4.30 (3.47-5.67) 4.56 (3.59-5.34) 0.8776
LDL cholesterol, mg/dl 98 (72-127) 105 (76-137) 0.2194
Fasting glucose, mg/dl 92 (86-97) 92 (86-97) 0.2243
Fasting insulin, pmol/l 54 (33-81) 37 (14-75) 0.1614
HOMA-IR 2.83 (1.66-4.20) 2.64 (1.54-4.78) 0.1392
All parameters expressed as median and (interquartile range) unless otherwise specified. BMI = body mass index, WHR = waist-to-hip ratio, BP =
blood pressure, BMC = Bone mineral content, BMD = Bone mineral density, HDL = High-density lipoprotein, LDL = Low-density lipoprotein,
HOMA-IR = homeostasis model assessment method.
doi:10.1371/journal.pone.0089088.t003
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Metabolic and body composition parameters over time
Changes in metabolic and fat parameters are summarized in
table 3. There were no statistically significant improvements in
metabolic or insulin sensitivity parameters. There were no
differences in the percentage of patients with total cholesterol
$140 mg/dl at baseline and at week 48 (23.8% vs. 21.4%), or in
LDL cholesterol $130 mg/dl (26.2% vs. 33.3%), HDL cholesterol
#40 mg/dl (38.1% vs. 42.8%) and triglycerides $150 mg/dl
(38.1% vs. 33.3%). Eleven patients (26.2%) were receiving lipid-
lowering drugs at baseline and 16 (38.1%) at week 48 (P = 0.3500).
All the patients had clinically-evident HALS. All the patients
had lipoatrophy, but in addition 20 (47.6%) presented also with
lipohypertrophy. No correlation between appendicular fat at
baseline and prior exposure to d4T both in months and grams
(r = 0.064, P = 0.6893) was found. Seventeen patients (40.5%) at
baseline and 11 (26.2%) at week 48 had ,3 kg of limb fat
(OR = 1.92; 95%CI = 0.69-5.39, P = 0.2472). The median LSGS
score at baseline was 8 (IQR: 8-12) and 8 (IQR: 7-10) at week 48
(P = 0.0070). The median facial score was 2 (IQR: 2-3) at 2 (IQR:
2-2) at week 48 (P = 0.0049). The median limb fat gain at 48 weeks
was 800 grams (IQR: 270-1400). Whole body fat and limb fat mass
increased significantly (Table 3). The median percent increase in
limb fat mass was 20.9% (IQR: 7.4-33.6%). Twenty-two patients
(52.4%) had an increase in limb fat $20% of baseline value.
Indices of fat distribution symmetry showed significant improve-
ments (Table 3). There was no correlation either between objective
fat gain and LSGS score improvement (r = 0.109, P = 0.5211). No
correlation between appendicular fat gain and prior exposure to
d4T both in months and grams (r = 0.144, P = 0.3944). Trunk fat,
lean mass, bone mineral content and bone mineral density did not
change significantly.
A logistic regression analysis was performed taking increase in
limb fat (, or $800 g) as the dependent variable and as
independent all those baseline variables with a P,0.1 in univariate
analyses (Table 4), and baseline weight. Baseline parameters
independently associated with limb fat gain $800 grams were:
baseline left leg fat (OR = 1.12; 95%CI: 1.00-1.25, P = 0.048, per
100 g) and length of HIV infection (OR = 0.83; 95%CI: 0.71-0.98,
P = 0.023, per year).
SAT gene expression changes over time
Paired fat biopsies were available for 18 patients. Demographic,
viro-immunological, metabolic and fat parameters of these
patients were not different from the whole study group. PPAR
gamma and adiponectin gene expression significantly increased
from baseline (Figure 1). The relative abundance of mtDNA and
Cyt b gene expression also significantly increased whereas Cox IV
gene expression did not change significantly (Figure 1). TNF alpha
and CD68 gene expression did not change significantly, although
MCP-1 gene expression significantly increased (Figure 1). No
correlation was found between limb fat gain and molecular
markers change in SAT.
Discussion
Our study shows that patients with long-lasting exposure to
d4T, who have developed HALS, experienced a significant limb
fat gain after switching to RAL. Consequently, indexes of body fat
distribution symmetry also showed improvement after switching.
Furthermore, fat gains were accompanied by improvements in
gene markers of adipocyte differentiation and mitochondrial
function at SAT level. Unfortunately, the objective fat gain did
not translate into a benefit perceived by the patient, as occurs in
other studies [4]. On the other hand, switching to RAL did not
improve dyslipidemia and insulin sensitivity. Other body com-
partments such as lean mass, bone mineral content, and bone
mineral density were unaffected by switching. No conclusion can
be drawn from this study in terms of virologic efficacy of such a
switch.
Table 4. Baseline parameters significantly associated with limb fat gain ($800 g limb fat) at week 48 on bivariate analysis.
Parameter Limb fat gain ,800 g (N = 21) Limb fat $800 g (N = 21) P value
Age in years, median (IQR) 47.0 (43.7-50.0) 43.0 (40.5-47.0) 0.0321
Years since diagnosis, years 13 (10-15) 7 (6-12) 0.0105
HCV treatment completed, n (%) 5 (23.8) 0 (0) 0.0478
Baseline CD4, cells/mm3 725 (434-935) 442 (367-699) 0.0682
CD4 increase (IQR), cells/mm3 534 (358-690) 355 (199-492) 0.0296
Baseline viral load, log10, copies/ml 1.28 (1.28-1.28) 1.28 (1.28-1.28) 0.0449
No. of HAART regimens 5 (4-7) 5 (2-8) 0.0814
HAART duration, months 131 (122.5-152.2) 98 (67.7-139.5) 0.0870
Left leg fat, g 881 (614-1298) 1131 (935-2024) 0.0394
Limb fat, g 2805 (2222-4618) 3738 (2928-5943) 0.0719
Trunk/limb fat ratio 2.39 (1.88-3.66) 1.91 (1.46-2.42) 0.0761
HDL cholesterol, mg/dl 45 (39-62) 40 (32-45) 0.0761
HOMA-IR 3.14 (2.40-12.38) 1.69 (1.47-2.93) 0.0152
All values expressed as median (IQR = interquartile range) unless otherwise specified, MsM = men who have sex with men, HTSX = heterosexuals,
IDU = intravenous drug users, AIDS = acquired immune deficiency syndrome, HCV = hepatitis C virus, CD4 increase = current CD4-CD4 prior to
starting of antiretroviral therapy, IQR = interquartile range.
Variables not associated with limb fat gain $800 g with a P value ,0.1 were: sex, means of HIV infection, smoking, prior AIDS, HCV co-infection,
Nadir CD4 cell count ,100 and ,200 cells/mm3, maximum viral load .5 log10 copies/ml, ART before switching, NRTI backbone before switching,
cumulated exposure for AZT, d4T, ddI and ddC, weight, BMI, waist circumference, WHR, systolic and diastolic BP, whole body fat, trunk fat, baseline
limb fat ,3 kg, fat mass ratio, fat mass index, percentage of left fat normalized by BMI, metabolic syndrome, total cholesterol, triglycerides, total
cholesterol/HDL ratio, LDL cholesterol, fasting glucose, and fasting insulin.
doi:10.1371/journal.pone.0089088.t004
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Switching from thymidine analogues to mitochondrially-friendly
NRTI has been a popular strategy in recent years for lipoatrophy
reversal. The rationale for this strategy is the well-known
mitochondrial toxicity of thymidine analogues and the apparent
lack of this toxicity of ABC and TDF [4,5,19,20]. When d4T was
switched to ABC or TDF, the increase in limb fat mass ranged
from 329 to 493 grams after 48 weeks [4,5]. The median amount
of limb fat mass gain in the present study compares favorably to
those reported in MITOX and RAVE trials [4,5]. This can be due
to the fact that RAL has no known toxic effects on mitochondria
whereas ABC and TDF still exhibit some degree of mitochondrial
toxicity. In vitro studies do not show a complete absence of toxicity
on mitochondria for either ABC or TDF [21]. An ex vivo sub-study
of ACTG 5224s showed a decrease in mtDNA fat content in
patients on ABC- and TDF-based regimens [22,23]. In the fat sub-
study of the MONOI study, patients randomized to the boosted
protease inhibitor (PI) monotherapy arm experienced a limb fat
gain of 340 grams over 48 weeks, unlike what happened in the
triple therapy control arm [24]. It is interesting to note that 79% of
the NRTI discontinued in the MONOI study were ABC or TDF
[24]. Furthermore, TDF toxicity is of mitochondrial etiology in
other cell types such as renal proximal tubular cells [25]. Taken
together, all these data suggest some low-level mitochondrial
toxicity which in the event of long-lasting exposure may cause fat
loss or may impede its recovery.
In our study two baseline variables were independently
associated with a greater limb fat recovery, these being the length
of HIV infection and baseline left leg fat. This suggests a concerted
action of both the deleterious effects of HIV infection and
prolonged exposure to antiretrovirals on the ability of SAT to
recover. This is in line with the fact that HIV and antiretroviral
drugs are able to affect biology and function not only of adipocytes
but also of adipocyte precursor cells [26-28]. Furthermore, in
patients exposed to AZT the length of exposure was an important
variable determining the amount of baseline fat [29].
There have been two switching clinical trials with RAL [30,31].
In both studies, patients on a stable boosted PI regimen had the PI
changed for RAL, and such a switch was followed by significant
improvement in lipid parameters in both studies, although fat was
only studied in SPIRAL [32]. In this study there were no
significant changes in the amount of limb fat between both arms
[32]. However, it should be taken into account that the NRTI
backbone was preserved throughout the study, and this included
ABC or TDF in 77% of the patients.
Figure 1. Changes in molecular markers in subcutaneous fat of patients with HALS switched from stavudine to raltegravir. Samples
were retrieved at baseline and at week 48. Box plots show median, IQR and maximum and minimum values for each variable. mtDNA =
mitochondrial DNA. PPAR gamma = peroxisome proliferator-activated receptor gamma. MCP-1 = monocyte chemotactic protein 1. TNF alpha =
tumor necrosis factor alpha. Cox IV = cytochrome oxidase subunit IV. mtDNA = mitochondrial DNA. nDNA = nuclear DNA.
doi:10.1371/journal.pone.0089088.g001
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We did not see any improvement in terms of dyslipidemia or
insulin sensitivity. The use of d4T has been associated with
hypercholesterolemia, hypertriglyceridemia and insulin resistance
[20,33]. The lack of improvement in metabolic parameters among
our patients can be attributed to the fact that most of our patients
(i.e. 64%) remained exposed to boosted PIs which are major
contributors to the appearance of dyslipidemia and insulin
resistance in HIV-infected patients [34].
The molecular findings of our study are in line with known drug
side-effects and also with the observed fat changes. The well-
known mitochondrial toxicity of d4T is exemplified by the
significant increase in mtDNA and Cyt b, a subunit of the
respiratory mitochondrial chain encoded by mtDNA [35]. On the
other hand, the expression of Cox IV, which is encoded by nuclear
DNA, was not significantly modified by switching. Both PI and
NRTI exhibit deleterious effects on adipocyte biology and
function, both in in vitro models and in ex vivo fat samples [35].
NRTI can impair adipocyte differentiation through down-
regulation of PPAR gamma and C/EBP alpha [36,37]. In
addition, thymidine analogues also impair adiponectin adipocyte
expression, an adipokine which sensitizes to insulin action and
which has anti-inflammatory action [38-40]. In contrast, RAL has
been reported to minimally affect adipocyte differentiation and
metabolism, including unaltered adipogenic gene expression
[41,42]. Therefore, the improvement in PPAR gamma and
adiponectin gene expression was expected after d4T withdrawal
because of the neutral effect of RAL on the expression of these two
genes. Furthermore, the present reported changes in adipose tissue
gene expression are likely to be biologically and functionally
relevant. Changes in the expression of PPAR gamma and PPAR
gamma-responsive genes such as adiponectin have been signifi-
cantly related to limb fat mass, further underscoring the
importance of PPAR gamma expression in the development of
lipoatrophy [36,43].
Inflammation is a powerful force in the pathogenesis of HALS
[1]. Data from the Lipostop trial suggest that d4T is directly
involved in the generation of a pro-inflammatory environment in
SAT of patients with HALS [44], and consequently d4T
withdrawal was associated with a decrease in CD68 gene
expression. This meant a decrease in macrophage infiltration at
SAT level [44]. Our data are at odds with those of the Lipostop
study since we did not observe significant changes neither in CD68
or in TNF alpha gene expression, and these changes occurred
together with a significant increase in MCP-1 transcripts. The
absence of improvement in the fat inflammatory status despite
increased fat mass may be related to the persistence of systemic
metabolic alterations since inflammation in SAT has been closely
related to the induction of insulin resistance and dyslipidemia in
metabolic pathologies such as obesity or congenital lipodystrophy
[45].
Our study has inherent limitations. First, it is an observational
study and therefore no causal relationship should or must be
drawn. The lack of control arm is an important limitation of the
study, but the evidence linking d4T exposure and HALS was so
overwhelming when the study was designed, that having a control
arm was not considered for ethical reasons [46]. Second, our study
is of limited duration, but its time span was sufficient to show a
significant improvement in limb fat and in SAT molecular
parameters. Alternatively there could be differences in cell
populations not reflected by differences in gene transcripts. The
evolving trend of limb fat beyond 48 weeks would probably not be
so pronounced in terms of gain, but we can only speculate about
that. Third, our sample size is small and this may prevent
achieving statistically significant results for some variables that
show a trend to significance. Fourth, the clinical significance of
switching from d4T to RAL is of limited usefulness in resource-
rich settings and even in those with limited resources, but our
study demonstrates that it can be useful for those cases that may
exist.
In summary, switching from d4T to RAL in patients with
HALS induces a remarkable increase in limb fat mass with and
improvement of molecular markers of adipocyte differentiation
and mitochondrial function in SAT, without beneficial effects on
dyslipidemia or insulin sensitivity.
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